Document -

Pelago Bioscience AB enters into CETSA™ method licensing agreement with GlaxoSmithKline

Pelago Bioscience AB has entered into a licensing agreement with GlaxoSmithKline (GSK) for the use of the Cellular Thermal Shift Assay (CETSA™) for determination and quantification of drug–target interactions. Under the agreement, Pelago Bioscience grants GSK a license to the CETSA method for use in research & development.
go to media item
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
File format:
.pdf
Download
Enter your email address to follow Pelago Bioscience AB

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Pelago Bioscience AB.

Okay